173 related articles for article (PubMed ID: 22410750)
1. Prophylaxis and treatment of GVHD after allogeneic haematopoietic SCT: a survey of centre strategies by the European Group for Blood and Marrow Transplantation.
Ruutu T; van Biezen A; Hertenstein B; Henseler A; Garderet L; Passweg J; Mohty M; Sureda A; Niederwieser D; Gratwohl A; de Witte T
Bone Marrow Transplant; 2012 Nov; 47(11):1459-64. PubMed ID: 22410750
[TBL] [Abstract][Full Text] [Related]
2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
3. A survey of the prophylaxis and treatment of acute GVHD in Europe: a report of the European Group for Blood and Marrow, Transplantation (EBMT). Chronic Leukaemia Working Party of the EBMT.
Ruutu T; Niederwieser D; Gratwohl A; Apperley JF
Bone Marrow Transplant; 1997 Apr; 19(8):759-64. PubMed ID: 9134165
[TBL] [Abstract][Full Text] [Related]
4. [Second transplantation for graft failure after allogeneic hematopoietic stem cell transplantation--a retrospective survey by Kanto Study Group for Cell Therapy].
Hagihara M; Kanamori H; Sakai M; Mori T; Nakaseko C; Aotsuka N; Uehara T; Sakura T; Yoshiba F; Kawai N; Tanaka M; Fujisawa S; Ohwada C; Wakita H; Yokota A; Kawamura T; Maruta A; Sakamaki H; Okamoto S;
Rinsho Ketsueki; 2010 Jun; 51(6):390-7. PubMed ID: 20622484
[TBL] [Abstract][Full Text] [Related]
5. Acute GVHD is a strong predictor of full donor CD3+ T cell chimerism after reduced intensity conditioning allogeneic stem cell transplantation.
El-Cheikh J; Vazquez A; Crocchiolo R; Furst S; Calmels B; Castagna L; Lemarie C; Granata A; Ladaique P; Oudin C; Faucher C; Chabannon C; Blaise D
Am J Hematol; 2012 Dec; 87(12):1074-8. PubMed ID: 22911907
[TBL] [Abstract][Full Text] [Related]
6. Use of intrathecal prophylaxis in allogeneic haematopoietic stem cell transplantation for malignant blood diseases: a survey of the European Group for Blood and Marrow Transplantation (EBMT).
Ruutu T; Corradini P; Gratwohl A; Holler E; Apperley J; Dini G; Rocha V; Schmitz N; Socié G; Niederwieser D
Bone Marrow Transplant; 2005 Jan; 35(2):121-4. PubMed ID: 15543201
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of folinic acid in preventing oral mucositis in allogeneic hematopoietic stem cell transplant patients receiving MTX as prophylaxis for GVHD.
Sugita J; Matsushita T; Kashiwazaki H; Kosugi M; Takahashi S; Wakasa K; Shiratori S; Ibata M; Shono Y; Shigematsu A; Obara M; Fujimoto K; Endo T; Nishio M; Kondo T; Hashino S; Tanaka J; Asaka M; Imamura M
Bone Marrow Transplant; 2012 Feb; 47(2):258-64. PubMed ID: 21423118
[TBL] [Abstract][Full Text] [Related]
8. Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation.
Pérez-Simón JA; Caballero D; Diez-Campelo M; Lopez-Pérez R; Mateos G; Cañizo C; Vazquez L; Vidriales B; Mateos MV; Gonzalez M; San Miguel JF
Leukemia; 2002 Aug; 16(8):1423-31. PubMed ID: 12145680
[TBL] [Abstract][Full Text] [Related]
9. Reducing transplant-related mortality after allogeneic hematopoietic stem cell transplantation.
Bacigalupo A; Sormani MP; Lamparelli T; Gualandi F; Occhini D; Bregante S; Raiola AM; di Grazia C; Dominietto A; Tedone E; Piaggio G; Podesta M; Bruno B; Oneto R; Lombardi A; Frassoni F; Rolla D; Rollandi G; Viscoli C; Ferro C; Garbarino L; Van Lint MT
Haematologica; 2004 Oct; 89(10):1238-47. PubMed ID: 15477210
[TBL] [Abstract][Full Text] [Related]
10. Prophylaxis with sirolimus and tacrolimus ± antithymocyte globulin reduces the risk of acute graft-versus-host disease without an overall survival benefit following allogeneic stem cell transplantation.
Rosenbeck LL; Kiel PJ; Kalsekar I; Vargo C; Baute J; Sullivan CK; Wood L; Abdelqader S; Schwartz J; Srivastava S; Abonour R; Robertson MJ; Nelson RP; Cornetta K; Fausel CA; Farag SS
Biol Blood Marrow Transplant; 2011 Jun; 17(6):916-22. PubMed ID: 20932925
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic stem cell transplantation as treatment for heavily treated, refractory acute graft-versus-host disease after HLA-mismatched stem cell transplantation.
Ikegame K; Yoshihara S; Taniguchi Y; Kaida K; Inoue T; Okada M; Taniguchi K; Hasei H; Tamaki H; Fujioka T; Kato R; Soma T; Ogawa H
Exp Hematol; 2011 Aug; 39(8):880-90. PubMed ID: 21689724
[TBL] [Abstract][Full Text] [Related]
12. Development of leukemia in donor cells after allogeneic stem cell transplantation--a survey of the European Group for Blood and Marrow Transplantation (EBMT).
Hertenstein B; Hambach L; Bacigalupo A; Schmitz N; McCann S; Slavin S; Gratwohl A; Ferrant A; Elmaagacli A; Schwertfeger R; Locasciulli A; Zander A; Bornhäuser M; Niederwieser D; Ruutu T;
Haematologica; 2005 Jul; 90(7):969-75. PubMed ID: 15996934
[TBL] [Abstract][Full Text] [Related]
13. A single centre experience with allogeneic stem cell transplantation for severe aplastic anaemia in childhood.
Ladenstein R; Peters C; Minkov M; Emminger-Schmidmeier W; Mann G; Höcker P; Hawliczek R; Rosenmayr A; Fink FM; Niederwieser D; Gadner H
Klin Padiatr; 1997; 209(4):201-8. PubMed ID: 9293451
[TBL] [Abstract][Full Text] [Related]
14. Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation.
Penack O; Marchetti M; Ruutu T; Aljurf M; Bacigalupo A; Bonifazi F; Ciceri F; Cornelissen J; Malladi R; Duarte RF; Giebel S; Greinix H; Holler E; Lawitschka A; Mielke S; Mohty M; Arat M; Nagler A; Passweg J; Schoemans H; Socié G; Solano C; Vrhovac R; Zeiser R; Kröger N; Basak GW
Lancet Haematol; 2020 Feb; 7(2):e157-e167. PubMed ID: 32004485
[TBL] [Abstract][Full Text] [Related]
15. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT).
Aoudjhane M; Labopin M; Gorin NC; Shimoni A; Ruutu T; Kolb HJ; Frassoni F; Boiron JM; Yin JL; Finke J; Shouten H; Blaise D; Falda M; Fauser AA; Esteve J; Polge E; Slavin S; Niederwieser D; Nagler A; Rocha V;
Leukemia; 2005 Dec; 19(12):2304-12. PubMed ID: 16193083
[TBL] [Abstract][Full Text] [Related]
16. Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed hematologic malignancy following autologous stem cell transplantation.
Dey BR; McAfee S; Sackstein R; Colby C; Saidman S; Weymouth D; Poliquin C; Vanderklish J; Sachs DH; Sykes M; Spitzer TR
Biol Blood Marrow Transplant; 2001; 7(11):604-12. PubMed ID: 11760148
[TBL] [Abstract][Full Text] [Related]
17. Sirolimus immunosuppression for graft-versus-host disease prophylaxis and therapy: an update.
Cutler C; Antin JH
Curr Opin Hematol; 2010 Nov; 17(6):500-4. PubMed ID: 20717025
[TBL] [Abstract][Full Text] [Related]
18. [Allogeneic hematopoietic stem cell transplantation in patients with chronic myeloid leukemia in the Czech Republic--a retrospective analysis of results in years 1988-2005].
Faber E; Koza V; Vítek A; Mayer J; Sedlácek P; Zák P; Zapletalová J; Benesová K; Krejcová H; Steinerová K; Maresová I; Cetkovský P
Vnitr Lek; 2006 Dec; 52(12):1172-80. PubMed ID: 17299910
[TBL] [Abstract][Full Text] [Related]
19. GvHD prophylaxis with tacrolimus plus sirolimus after reduced intensity conditioning allogeneic transplantation: results of a multicenter study.
Parody R; López-Corral L; Lopez-Godino O; Martinez C; Martino R; Solano C; Barba P; Caballero D; García-Cadenas I; Piñana JL; Marquez-Malaver FJ; Vazquez L; Esquirol A; Boluda JC; Sanchez-Guijo F; Pérez-Simon JA
Bone Marrow Transplant; 2016 Nov; 51(11):1524-1526. PubMed ID: 27295268
[No Abstract] [Full Text] [Related]
20. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning.
Ogawa H; Ikegame K; Yoshihara S; Kawakami M; Fujioka T; Masuda T; Taniguchi Y; Hasei H; Kaida K; Inoue T; Kim EH; Kawase I
Biol Blood Marrow Transplant; 2006 Oct; 12(10):1073-84. PubMed ID: 17084371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
